KonstantinidesSVMeyerGBecattiniC, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J2020; 41: 543–603.
3.
INSPIRATION Investigators, SadeghipourPTalasazAH, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA2021; 325: 1620–1630.
4.
ChatterjeeSChakrabortyAWeinbergI, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA2014; 311: 2414–2421.
5.
PiazzaG.Advanced management of intermediate-and high-risk pulmonary embolism: JACC focus seminar. J Am Coll Cardiol2020; 76: 2117–2127.
6.
MeyerGVicautEDanaysT, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med2014; 370: 1402–1111.
7.
RothschildDPGoldsteinJABowersTR.Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: clinical efficacy but attendant hemorrhagic risks. Catheter Cardiovasc Interv2019; 93: 506–510.
8.
SharifiMBayCSkrockiL, et al. Moderate pulmonary embolism treated with thrombolysis (from the ‘MOPETT’ trial). Am J Cardiol2013; 111: 273–277.
9.
GünerAKalçikMAykanAÇ, et al. Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism. Blood Coagul Fibrinolysis2020; 31: 536–542.
